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Abstract 
 
Objective 
To review the differences between male and female lupus patients with respect 
to clinical features, serology and outcome over a thirty year period. 
 
Material and methods 
An observational study of all SLE patients seen at the University College of 
London Hospital between 1976 and 2005 was performed. Demographic, clinical 
and serological data and outcome were retrospectively collected from hospital 
records or questionnaires and reviewed.  
Comparisons between continuous variables were made using Kruskal Wallis 
test. Chi-square test or Fisher´s exact test were used for categorical variables 
when it was appropriate. 
 
Results 
484 patients (439 females and 45 males) were identified between 1976 and 
2005. Their mean age at diagnosis was 29.3 years (12.6) with no significant 
differences between men and women. There were no significant differences 
between the number of men and women diagnosed at the different decades or 
in the mean age at diagnosis.  Female gender was significantly associated with 
the presence of oral ulcers (29.2% vs 13.3%, p<0.05) and Ig M ACA (9.9% vs 
0%, p<0.05). There were no significant differences in the comparison of other 
variables. 
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With respect to outcome, although renal failure and death were higher in 
females (7.7% vs 5.4% and 15.1% vs 8.1% respectively), no statistically 
significant differences were found. Cardiovascular disease was the commonest 
cause of death in men. 
 
Conclusion 
Over this thirty year follow up period, relatively few differences have emerged 
comparing the frequencies of clinical and serological features or outcome in 
male and female lupus patients. 
 
Keywords: Systemic lupus erythematosus; Clinical features; Serology; Death; 
Renal Failure. 
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Introduction 
 
Systemic lupus erythematosus (SLE) is a clinically heterogeneous 
autoimmune disease characterized by the presence of autoantibodies directed 
against nuclear antigens. It is, by definition, a multi-system disease, and 
patients present in many different ways, in terms of clinical and immunological 
manifestations [1]. The pathogenesis and etiology remain unclear, but multiple 
genetic and environmental factors are likely to play a role in its pathogenesis [2-
3]. 
 SLE is up to 10 times more common in women than men during the child 
bearing years [4]. An increase in frequency of SLE among females is believed 
to be related to the effect of endogenous sex hormones which has been 
discussed in several reviews [5-11]. Sex hormones have been shown to interact 
with the immune system, including the B cell and T cell compartment, dendritic 
cells and cytokine networks. It is thought that female sex hormones cause the 
enhanced autoimmune reactivity and contribute to the immunological 
perturbation that results in SLE. The female hormonal influences include 
supporting the survival of autoreactive B cells and modifying their maturation 
toward a marginal zone phenotype, while male hormones produce the opposite 
effects. Further evidence comes from the fact that the ratio of female to male 
cases is much lower in prepuberal children and after menopause, although a 
female predominance remains [12-14].  
 Since 1975 a number of articles have been published analyzing the 
differences between male and female SLE. In general, the results of these 
studies revealed that male patients develop similar typical clinical 
 6  
manifestations of lupus as in females, although male SLE may have some 
distinguishing frequencies of organ involvement notably haematological [15, 
16], neurological involvement [17, 16] or nephritis [15, 18]. Variable reports of 
the prognosis of lupus in males (worse or the same) compared to females have 
also been published [15, 19].  
 We were interested to review our male and female lupus patients with 
respect to clinical features, serology and outcome over a thirty year period. We 
wondered whether there might be a discernable difference over time. Thus we 
have divided the patients who entered the cohort into three decades, from 1976 
to 1985, from 1986 to1995 and from 1996 to 2005, and now report on our 
observations over this long period of time. 
 
 
Material and methods 
 
Patients 
 484 patients with SLE were followed up in the Centre for Rheumatology 
at University College of London Hospital (UCLH) and were stratified by year of 
lupus diagnosis in three groups (from 1976 to 1985, from 1986 to 1995, from 
1996 to 2005). All patients diagnosed outside these periods, were excluded. 
 SLE was diagnosed when a fourth ACR diagnostic criterion (1982, 
revised in 1997) developed [20, 21]. 
 
 
Collection of clinical and serological data 
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 Demographic, clinical and serological data were retrospectively reviewed 
from hospital records or questionnaires and reviewed. 
 We recorded clinical features and serological data as present or absent 
and considered them as cumulative clinical features and serological data at 
diagnosis respectively. 
 Clinically we recorded rash, photosensitivity, alopecia, oral ulcers, 
arthritis, serositis, nephritis, central nervous system (CNS) involvement, 
haemolytic anaemia, leucopenia, lymphopenia, thrombopenia, Sjögren´s, 
antiphospholipid syndrome (APS) and myositis. 
 We reviewed serological data notably antinuclear antibodies (ANA) 
measured by indirect immunofluorescence using Hep-2 as the substrate 
(positive ANA at ≥ 1:80), rheumatoid factor (RF) measured by the latex test and 
RAPA (agglutination assay) technique (positive RF at ≥ 1:80), antibodies to 
extractable nuclear antigens (ENA), including Sm, RNP, Ro, La, measured by 
enzyme-linked immunosorbent assay (ELISA), anti-ds DNA measured by ELISA 
and indirect inmunofluorescence with Crithidia Lucidae as the substrate, lupus 
anticoagulant (LAC) measured by Dilute Russell Viper Venom Screen (DRVVT),  
anticardiolipin (IgM and IgG ACA) antibodies measured by ELISA and C3 
measured by laser nephelometry.  
 With respect to outcome, we took into account death (early death defined 
as <50y and late death as ≥50y) and renal failure, taking the latter to be the 
need for dialysis or renal transplant. 
 
Statistical analysis 
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 All data were analyzed using SPSS 15.0 software. Continuous variables 
were described as mean with standard deviation (SD) and categorical variables 
were described as percentages. Clinical and serological manifestations of SLE 
were compared between male and female lupus patients in the three periods, of 
diagnosis, groups. Comparisons between continuous variables were made 
using Kruskal Wallis test. Chi-square test or Fisher´s exact test were used for 
categorical variables when it was appropriate. A probability level less than 0.05 
in two-tailed test was used as the criterion of significance. 
 
 
Results 
 
 The total cohort consisted of 484 patients diagnosed from 1976 to 2005, 
45 (9.3%) males and 439 females (90.7%); the ratio of female to male was 
9.7:1. The mean age at diagnosis was 29.3 years (12.6) with no significant 
differences between the male and female means which were 30.9 years (15.6) 
and 29.1 years (12.2) respectively (Fig 1a and Fig 1b).  
 
The majority of patients (58.7%-284 patients) were Caucasian, 21.7% 
(105 patients) Afro-Caribbean, 11.6% (56 patients) South Asian (India, 
Pakistan, Bangladesh), 5,4% (26 patients) Chinese and 2.7% mixed ethnicities.  
 
 Stratifying patients by gender and race, it is noteworthy that, among the 
male patients, 13.3% (6 patients) were Afro-Caribbean, 17.8% (8 patients) 
Asian, 66.7% (30 patients) Caucasian and 2.2% (1 patient) Chinese; whereas 
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among the female population, 22.6% (99 patients) were Afro-Caribbean, 10.9% 
(48 patients) Asian, 57.9% (254 patients) Caucasian, 5.7% (25 patients) 
Chinese and 3% mixed ethnicities.  
 The ratio of female to male was different in these four groups, in Afro-
Caribbeans 16.5:1, in Asians 6:1, in Caucasians 8.4:1 and in Chinese 25.3:1. 
However, due to the limited sample in some of the subgroups, although a trend 
could be observed, the differences are not statistically significant. 
 Analyzing the mean age at diagnosis of men and women in different 
races, we found significant differences between these groups with a p value of 
0.004, although again, some populations were so small, that it could distort the 
results (Table 1). 
 
 The vast majority of patients in our lupus cohort (83.3%-403 patients) 
were diagnosed between ages of 15 and 49. However, 7.9% (38 patients) out of 
these patients developed lupus over the age of 50 and 8.9% (43 patients) under 
the age of 14. 
 Considering the male patients, 13.3% (6 patients) were diagnosed before 
14 years of age, 75.6% (34 patients) between 15 and 49 years old and 11.1% 
(5 patients) between 50 and 79. In the female population, 8.4% (37 patients) 
were diagnosed before 14 years of age, 84.1% (369 patients) between 15 and 
49 years old and 7.5% (33 patients) between 50 and 79. 
 The ratio of female to male in these three groups was different, in the 
young onset group (under 14 years) it was 6.14:1, in the adult onset group (15-
49 years) 10.9:1 and in older onset group (over 50 years) 6.6:1. Again, no 
statistically significant difference between these groups was evident. 
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 Regarding the distribution of our population in three decades, 23% (115 
patients) were diagnosed between 1976 and 1985, 33.9% (164 patients) 
between 1986 and 1995 and 42.4% (205 patients) between 1996 and 2005. 
There were no significant differences between the number of men and 
women diagnosed during the different decades. There were also no significant 
differences in the mean age at diagnosis between male and female in these 
three groups as seen in Table 2. 
 
 In Table 3 and 4 the cumulative clinical features and serology of the male 
and female patients, divided into the three decades, are shown. 
  
 Female gender was significantly associated with the presence of oral 
ulcers (29.2% vs 13.3%, p < 0.05) and Ig M anticardiolipin antibodies (ACA) 
(9.9% vs 0%, p < 0.05). There were no significant differences in the comparison 
of the other variables, although, interestingly, dermatological manifestations 
were more frequent in females, in the whole cohort and in each decade; and no 
man suffered from concomitant myositis. Sjögren´s and APS were also more 
frequent in females, although no significant differences were found. 
 Analysing the serological data, the presence of anti-Sm antibodies was 
more frequent in the female group (15.3% vs 8.9%). Anti-ds DNA antibodies 
were observed in 71.1% of males compared to 66.7% of females, however, 
complement (C3) was reduced in a 37.8% and 48.7% respectively. These 
differences were not significant. 
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 In the whole cohort, renal failure was higher in females (7.7% vs. 5.4%) 
as was death, 15.1% (10.4% early death) in females and 8.1% (2.7% early 
death) in males. No statistically significant difference was found (Table 5).   
 The causes of death were variable in the female group (cardiovascular 
19%, renal 8.6%, infectious disease 27.6%, cancer 22.4% and others 22.4%) 
but in the male group cardiovascular disease (66.7%) and cancer (33.3%) 
occurred more often but were not significant different.  
 Renal disease as a cause of death decreased during the three decades, 
being responsible for 7.7% of deaths in female population between 1976 and 
1985, 5% between 1986 and 1995 and 0% between 1996 and 2005. 
 
 
Discussion    
 
 In the present study, we analyzed whether gender has an influence on 
the manifestations and outcome of SLE over 30 years (from 1976 to 2005). 
 There was no significant difference in the mean age at diagnosis 
between male and female patients, which was similar to previous studies [15, 
22] although it was slightly higher in men as reported in a previous study [17]. 
There was no statistically significant difference in the mean age at diagnosis 
between male and female patients over the three separate decades. However 
significant differences were found in the mean age at diagnosis between male 
and female patients in different ethnic groups, with Afro-Caribbean and Asian 
patients presenting earlier compared to Caucasian patients. 
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 In our study, the general ratio of female to male was 9.7:1; this ratio in 
adult onset group was 10.9:1, and decreased in younger and older onset 
groups (6.1:1 and 6.6:1 respectively), which is in agreement with previous 
studies [13, 14, 22].  
 Although a difference in the ratio of female to male in the different ethnic 
groups was observed, due to the small sample size of some of the groups, we 
can not draw any meaningful conclusions, as the differences were not 
statistically significant. 
   
 Most studies have reported a significantly higher prevalence of skin 
involvement in males as opposed to females [18, 23, 24]. Some studies 
founded that discoid and/or subacute lesions were more common in male 
patients but malar rash was less common [16, 25, 26]. In our analysis, we did 
not distinguish between different types of rash and, although there was no 
significant difference, a trend to the presence of rash being more frequent in 
females was noted. Our findings are in accordance with data from other studies 
[15, 27, 28]. 
 We also noted a female preponderance for photosensitivity [15, 22, 26] 
and alopecia [15, 22, 28, 29] as described previously, but this was not 
statistically significant. 
 The presence of oral ulcers in the present study was significantly higher 
in females compared to males. This result is similar to other series [22, 26, 30]. 
 In our cohort, we did not find differences between male and female SLE 
patients with respect to other clinical manifestations of SLE. However, some 
authors have detected higher frequency of the following features in male 
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patients: haematological involvement [15, 16, 27, 31, 32], serositis [16, 25, 26, 
33-35], neurological involvement [16, 17, 31, 36] and nephritis [15, 16, 18, 19, 
23, 26, 29, 31, 32, 37-39]. 
 In the current study, Sjogren´s, APS and myositis were more prevalent 
among female patients although the sample is too small to establish a 
statistically significant difference, but, interestingly no man developed myositis 
compared to 3.9% of the female patients.  
  
 With respect to serological findings, some studies have reported a 
decreased prevalence for anti-Ro [26, 30, 40] and anti-La [26, 29] antibodies in 
men. In the present series we have observed this trend, but it was not 
statistically significant. Anti-ds DNA antibodies were found to be more prevalent 
among males in our cohort, consistent with other studies [16, 24, 37], but, 
again, there was no statistically significant difference. The remaining 
autoantibodies in our patients were more frequent among females, including a 
low C3. IgM ACA was significantly higher among female population, and this 
result is in agreement with the report Garcia et al [15]. 
 
  In relation to outcome, we investigated the differences in mortality and 
renal failure (dialysis and/or renal transplant) between male and female SLE 
patients. Although we did not calculate comparative 5-, 10-, 15-year survival 
rates for males and females [41], death was observed in 15,1% of females 
compared to 8,1% of males (3 patients died), with no significant differences as 
noted in previous studies [15, 38]. Interestingly just 1 male patient (2.7%) died 
under than 50 years old, as compared to 10.4% in the female group although 
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this early death percentage has decreased over the time in agreement with 
other studies [42]. No men died as a result of renal disease, the causes 
identified in this group were cardiovascular disease (2 patients) and cancer (1 
patient). 
  In women, the causes of death were variable. Most deaths were due to 
infectious disease, cancer and cardiovascular disease in that order. In contrast 
cardiovascular causes were the most common in men. We should highlight that 
renal disease as a cause of death has decreased in the female population 
during the time studied; from 7.7% in the first period (1976-1985) to 5% in the 
second period (1986-1995) and 0% in the third period (1996-2005) as 
previously reported [43]. The reason is likely to be the improvement in diagnosis 
and treatment during this time.  
  Despite the decrease in renal disease as a cause of death, the incidence 
of infections as a cause of mortality has not changed over the last 30 years as 
was reported in a recent review [44].   
  Renal failure was slightly higher in females compared to males (7.7% vs. 
5.4% respectively) contrary to other studies [23, 39, 45, 46]. The percentage of 
renal failure in female population was lower in the third decade compared to the 
first (6% vs. 9.7%). In the male group just 2 patients presented with renal failure 
so it is not possible to compare the frequencies between the three decades.    
   
  This study has some limitations, for example we did not assess the 
influence of the variable duration of follow-up in the outcome because some 
patients moved away and the follow-up was difficult. However, the number of 
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lost-to-follow up is small (<20 patients) and thus unlikely to influence our results 
very significantly. 
 
 
Conclusions 
   
  Over fifteen years ago, one of us (DAI) wrote that attempting to identify 
the special characteristics of the male lupus patient was rather like “trying to 
spot the “Loch Ness” monster [47]. Many attempts have been made but none 
have truly convinced all of the observers”. Based on observations over a 30 
year period, in the current study this observation continues to be true. We 
analyzed the association of sex with clinical features and serological data. 
Except for oral ulcers and IgM ACA (more common in women), there were no 
significant difference in other common clinical and laboratory features between 
male and female lupus patients in each of the decades studied. 
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Fig 1a. Age distribution of SLE male patients at onset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1b. Age distribution of SLE female patients at onset. 
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Table 1. Male and Female mean age at diagnosis in different ethnic groups. 
 
Mean (SD) Afro-Caribbean Asian Caucasian Chinese 
Male 24 (7.874) 23 (14.948) 34.13 (16.199) 40 (1 patient) 
Female 28.78 (10.675) 23.94 (9.648) 30.85 (13.156) 25.8 (11.365) 
 
 
Table 2. Population distribution and mean age at diagnosis depending on 
the decade of diagnosis. 
 
 1976-1985 1986-1995 1996-2005 
N           % Mean (SD) N           % Mean (SD) N           % Mean (SD) 
Male 9        7.8% 36.3(13.51) 13      7.9% 26.38(15.18) 23   11.2% 31.39(16.38) 
Female 106  92.2% 30.51(10.92) 151  92.1% 28.15(11.63) 182 88.8% 29.16(13.41) 
Total 115  100% 30.97(11.19) 164   100% 28.01(11.90) 205  100% 29.41(13.74) 
 
 
 
Table 3. Cumulative clinical manifestations in different period of diagnosis: 
comparison between male and female patients.  
 
 Total 1976-1985 1986-1995 1996-2005 
Male 
(n=45) 
Female 
(n=439) 
Male 
(n=9)  
Female 
(n=106)  
Male 
(n=13) 
Female 
(n=151) 
Male 
(n=23) 
Female 
(n=182) 
Rash 29   64.4% 298   67.9% 6   66.7% 89   84% 7   53.8% 103  68.2% 16  69.6% 106  58.2% 
Photosensitivity 16   35.6% 185   42.1% 5   55.6% 53   50% 5   38.5% 66   43.7% 6    26.1% 66    36.3% 
Alopecia 7     15.6% 102   23.2% 0   0% 24   22.6% 2   15.4% 29   19.2% 5    21.7% 49    26.9% 
Oral Ulcers *6   13.3% *128   29.2%        3   33.3% 38   35.8% 1    7.7% 42    27.8%        2    8.7% 48    26.4%        
Artritis 42   93.3% 419   95.4% 9   100% 105  99.1% 13  100% 145  96% 20  87% 169  92.9% 
Serositis 19   42.2% 180   41% 5   55.6% 60   56.6% 7    53.8% 65    43% 7    30.4% 55    30.2% 
Nephritis 14   31.1% 157   35.8% 2   22.2% 33   31.1% 5    38.5% 59    39.1% 7    30.4% 65    35.7% 
CNS 12   26.7% 109   24.8% 3   33.3% 36   34% 4    30.8% 29    19.2% 5    21.7% 44    24.2% 
H. Anaemia 2     4.4% 20     4.6% 0   0% 5     4.7% 0    0% 6      4% 2    8.7% 9      4.9% 
Leucopoenia 12   26.7% 140   31.9% 5   55.6% 51   48.1% 5    38.5% 54    35.8% 2    8.7% 35    19.2% 
Lymphopenia 38   84.4% 329   74.9% 9   100% 83   78.3% 10  76.9% 113  74.8% 19  82.6% 133  73.1% 
Thrombopenia 5     11.1% 72     16.4% 0   0% 26   24.5% 2    15.4% 22    14.6% 3    13% 24    13.2% 
S. Jögren 3     6.7% 43     9.9% 3   33.3% 23   21.9% 0    0% 11    7.4% 0    0% 9       5% 
APS 1     2.2% 29     6.6% 0   0% 16   15.1% 0    0% 9      6% 1    4.3% 4       2.2% 
Myositis 0     0% 17     3.9% 0   0% 6     5.7% 0    0% 6      4% 0    0% 5       2.7% 
* p<0.05 
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Table 4. Serological data in different period of diagnosis: comparison between 
male and female patients.  
 
 Total 1976-1985 1986-1995 1996-2005 
Male 
(n=45) 
Female 
(n=439) 
Male 
(n=9) 
Female 
(n=106) 
Male 
(n=13) 
Female 
(n=151) 
Male 
(n=23) 
Female 
(n=182) 
ANA 42  93.3% 402  93.2% 8   88.9% 96   90.6% 13  100% 144  95.4% 21  91.3% 168   92.8% 
RF 10  22.7% 109  25.8% 2   22.2% 23   22.1% 4    30.8% 34    23.3% 4    18.2% 52    30.1% 
Sm 4    8.9% 67    15.3% 1   11.1% 6     5.7% 0    0% 24    15.9% 3    13% 37    20.3% 
RNP 9    20% 127  29% 2   22.2% 25   23.6% 3    23.1% 38    25.2% 4    17.4% 64    35.4% 
Ro 14  31.1% 171  39% 2   22.2% 34   32.1% 5    38.5% 55    36.4% 7    30.4% 82    45.3% 
La 5    11.1% 66    15.1% 1   11.1% 16   15.1% 2    15.4% 21    13.9% 2    8.7% 29    16% 
ds DNA 32  71.1% 291  66.7% 5   55.6% 63   59.4% 10  76.9% 96    64% 17  73.9% 132  73.3% 
Low C3 17  37.8% 213  48.7% 2   22.2% 38   35.8% 5    38.5% 77    51.3% 10  43.5% 98    54.1% 
LAC 5    11.4% 74    17.1% 0   0% 24   22.9% 3    23.1% 21    14.1% 2    9.1% 29    16.2% 
ACA IgG 9    20.5% 98    22.6% 2   22.2% 32   30.2% 2    15.4% 28    19% 5    22.7% 38    21% 
ACA IgM *0    0% *43    9.9% 0   0% 18   17% 0    0% 15    10.2% 0    0% 10    5.5% 
*p<0.05 
 
 
Table 5. Outcomes in the general population and in each decade. 
 
 Total 1976-1985 1986-1995 1996-2005 
Male Female Male Female Male Female Male Female 
Renal 
Failure 
5.4% 
(2p) 
7.7% 
(30p) 
0% 9.7% 
(9p) 
10% 
(1p) 
8.5% 
(11p) 
5.3% 
(1p) 
6% 
(10p) 
Early Death 
(<50y) 
2.7% 
(1p) 
10.4% 
(40p) 
12.5% 
(1p) 
14.1% 
(13p) 
0% 11.8% 
(15p) 
0% 7.2% 
(12p) 
Late Death  
(≥50y) 
5.4% 
(2p) 
4.7% 
(18p) 
12.5% 
(1p) 
14.1% 
(13p) 
0% 3.9% 
(5p) 
5.3% 
(1p) 
0% 
 
 
 
 
